Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00277
|
|||||
Drug Name |
Ipratropium
|
|||||
Synonyms |
(+-)-Ipratropine; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane; Aerodose; Aerovent; Apo-Ipravent; Apovent; Apovent (TN); Atronase; Atrovent; Atrovent (TN); Atrovent Aerosol; Atrovent Hfa; Atrovent Nasal; Bitrop; Disne-Asmol; Ipatropium Bromide; Ipratropium bromide; Ipravent; Ipvent; Kendral-Ipratropium; N-Isopropylatropine; Narilet; Rhinotrop; Rhinovent; Rinatec; Rinoberen; Rinovagos; Vagos; X8M; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Obstructive lung diseases [ICD11: CA22.Z] | Approved | [1] | |||
Therapeutic Class |
Bronchodilator Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C20H30NO3+
|
|||||
Canonical SMILES |
CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C
|
|||||
InChI |
InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1
|
|||||
InChIKey |
OEXHQOGQTVQTAT-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 60205-81-4
|
|||||
Pharmaceutical Properties | Molecular Weight | 332.5 | Topological Polar Surface Area | 46.5 | ||
Heavy Atom Count | 24 | Rotatable Bond Count | 6 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
XLogP |
2.6
|
|||||
PubChem CID | ||||||
PubChem SID |
103127404
, 104170067
, 104304400
, 11466603
, 11467723
, 11486345
, 117575154
, 121362439
, 124886805
, 124968912
, 126407694
, 128799107
, 135650410
, 136350344
, 136959634
, 140035998
, 141999271
, 142186678
, 142719345
, 160857166
, 162879438
, 166233201
, 172080692
, 176484704
, 179148622
, 179694577
, 226395381
, 237172531
, 239293942
, 242128594
, 244502426
, 246151890
, 248499359
, 26756583
, 29222866
, 47509536
, 50070857
, 5243543
, 5243557
, 6951281
, 79331559
, 8152369
, 85209499
, 85788108
|
|||||
ChEBI ID |
ChEBI:5956
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
OCTN1 | Transporter Info | Organic cation/carnitine transporter 1 | Substrate | [3] | ||
OCTN2 | Transporter Info | Organic cation/carnitine transporter 2 | Substrate | [3] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | OCT-1 | Transporter Info | Km = 9 microM | Human embryonic kidney cells (HEK293)-OCT1 | [2] | |
OCTN1 | Transporter Info | Km = 444 microM | Human embryonic kidney cells (HEK293)-OCTN1 | [3] | ||
OCTN2 | Transporter Info | Km = 53 microM | Human embryonic kidney cells (HEK293)-OCTN2 | [3] | ||
References | ||||||
1 | Ipratropium was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. | |||||
3 | Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.